Synermore Biologics (Suzhou) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2016-08-10
- Employees
- -
- Market Cap
- -
- Website
- http://synermore.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
Phase 3
Completed
- Conditions
- Rhabdoviridae InfectionsRNA Virus InfectionsRabiesCommunicable DiseaseVirus DiseasesMononegavirales Infections
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT04644484
- Locations
- 🇨🇳
Yunnan Province Center for Disease Control and Prevention (CDC), Kunming, China
A Bridging Study of the SYN023 on Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Rabies HumanVaccine ReactionCommunicable Disease TransmissionImmunisation ReactionZoonotic Disease
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT04495569
- Locations
- 🇨🇳
Jilin University, Changchun City, Jilin, China
News
No news found